Samsara Biocapital
$1.2B 13F equity value
26 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Samsara Biocapital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| SRRK | SCHOLAR ROCK HLDG CORP | 6,897,652 | $379M | 31.2% |
| ALMS | ALUMIS INC | 6,345,219 | $179M | 14.7% |
| MLYS | MINERALYS THERAPEUTICS INC | 5,871,018 | $158M | 13.0% |
| SEPN | SEPTERNA INC | 3,149,128 | $105M | 8.7% |
| ALMR | ALAMAR BIOSCIENCES INC | 2,480,310 | $67M | 5.5% |
| NGNE | NEUROGENE INC | 1,717,127 | $54M | 4.4% |
| KLRS | KALARIS THERAPEUTICS INC | 12,881,175 | $52M | 4.3% |
| SGP | SPYGLASS PHARMA INC | 2,109,953 | $47M | 3.9% |
| STRO | SUTRO BIOPHARMA INC | 1,062,872 | $35M | 2.9% |
| IVA | INVENTIVA SA | 6,314,805 | $24M | 2.0% |
Track Samsara Biocapital's 13F portfolio: $1.2B in reported holdings, 26 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}